Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
12:47pm, Thursday, 09'th Jun 2022
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
4 Supercharged Growth Stocks Billionaires Can't Stop Buying
09:21am, Wednesday, 08'th Jun 2022 The Motley Fool
Successful money managers piled into these fast-growing companies in the first quarter.
4 Supercharged Growth Stocks Billionaires Can't Stop Buying
05:21am, Wednesday, 08'th Jun 2022
Successful money managers piled into these fast-growing companies in the first quarter.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
01:45pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
02:10pm, Friday, 27'th May 2022 Zacks Investment Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
3 Stocks That Could Make You a Fortune Over the Next 10 Years
11:05am, Saturday, 21'st May 2022 The Motley Fool
They have one key common denominator.
3 Stocks That Could Make You a Fortune Over the Next 10 Years
07:05am, Saturday, 21'st May 2022
They have one key common denominator.
Can This Cancer Stock Maintain Its Momentum?
02:23pm, Wednesday, 18'th May 2022 The Motley Fool
This biotech stock has been on fire since the beginning of the year.
Exelixis: Becoming A Giant Pharma
11:20am, Wednesday, 18'th May 2022
Over the years, Exelixis' esteemed management successfully ramped up cabozantinib sales beyond the blockbuster range. Through many ongoing aggressive cabozantinib advancements, you can expect this blo
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
10:20am, Wednesday, 18'th May 2022 Zacks Investment Research
Smart Beta ETF report for XBI
Buying These 3 Stocks Could Be the Smartest Investing Move You Ever Make
03:00pm, Tuesday, 17'th May 2022 The Motley Fool
With thrilling long-term prospects, these three are excellent buys.
Exelixis (EXEL) Q1 2022 Earnings Call Transcript
07:00pm, Wednesday, 11'th May 2022 The Motley Fool
EXEL earnings call for the period ending March 31, 2022.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
06:08pm, Wednesday, 11'th May 2022 Zacks Investment Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
03:48pm, Wednesday, 11'th May 2022
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
